This is a working overview of investigational status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
== Chemistry == Icodextrin is a starch-derived, branched, water-soluble glucose polymer linked by α-(1→4) and less than 10% α-(1→6) glycosidic bonds, making it a type of dextrin. Its weight-average molecular weight is between 13,000 and 19,000 daltons and its number-average molecular weight between 5,000 and 6,500 daltons. The substance is a white to off-white solid, and the solution is clear and colourless to pale yellow.
Conformational subsets from this pool whose average theoretical parameters closely match known experimental data for this protein are selected. The alternative molecular dynamics approach takes multiple random conformations at a time and subjects all of them to experimental data. Here the experimental data is serving as limitations to be placed on the conformations (e.g. known distances between atoms). Only conformations that manage to remain within the limits set by the experimental data are accepted. This approach often applies large amounts of experimental data to the conformations which is a very computationally demanding task. The conformational ensembles were generated for a number of highly dynamic and partially unfolded proteins, such as Sic1/Cdc4, p15 PAF, MKK7, Beta-synuclein and P27
Lectins fractionate cells to avoid graft-versus-host disease in hematopoietic stem cell transplantation. Activation and expansion of cytolytic CD8 T cells in cancer treatment. Glycomics is particularly important in microbiology because glycans play diverse roles in bacterial physiology. Research in bacterial glycomics could lead to the development of:
The ionic radius is expected to decrease regularly for Mn2+ to Zn2+. This would be the normal periodic trend and would account for the general increase in stability. The crystal field stabilisation energy (CFSE) increases from zero for manganese(II) to a maximum at nickel(II). This makes the complexes increasingly stable. CFSE returns to zero for zinc(II). Although the CFSE for copper(II) is less than for nickel(II), octahedral copper(II) complexes are subject to the Jahn–Teller effect which results in a complex having extra stability. Another example of the effect of ionic radius the steady increase in stability of complexes with a given ligand along the series of trivalent lanthanide ions, an effect of the well-known lanthanide contraction.
the number of molecules, etc. in a given amount of material is a fixed dimensionless quantity that can be expressed simply as a number, not requiring a distinct base unit; the SI thermodynamic mole is irrelevant to analytical chemistry and could cause avoidable costs to advanced economies the mole is not a true metric (i.e. measuring) unit, rather it is a parametric unit, and amount of substance is a parametric base quantity the SI defines numbers of entities as quantities of dimension one, and thus ignores the ontological distinction between entities and units of continuous quantities the mole is often used interchangeably and inconsistently in online sources to refer to both a unit and a quantity without appropriate use of amount of substance causing confusion for novice chemistry students.
Sources: en.wikipedia.org
== History == The therapeutic efficacy of subcutaneous pegcetacoplan in treating paroxysmal nocturnal hemoglobinuria has been established through several clinical trials. Initial phase I and II trials, such as PADDOCK, PALOMINO, and PHAROAH, evaluated pegcetacoplan in participants with paroxysmal nocturnal hemoglobinuria who had not received a complement inhibitor or had previously received eculizumab. These trials demonstrated that 1–2 years of pegcetacoplan treatment effectively controlled hemolysis and improved quality of life in participants with paroxysmal nocturnal hemoglobinuria. Building upon these findings, the efficacy of pegcetacoplan was further assessed in phase III trials. The PRINCE trial, a 26-week study, focused on complement inhibitor-naïve participants with paroxysmal nocturnal hemoglobinuria, while the PEGASUS trial, a 48-week multinational study, included complement inhibitor-treated participants with paroxysmal nocturnal hemoglobinuria. In these trials, subcutaneous pegcetacoplan was administered at a dosage of 1080 mg twice weekly, delivered as a 20-mL subcutaneous infusion. Participants had the option to self-administer the medication or have it administered by qualified research personnel.
== Trade names == Several companies have attempted to trademark particular strains, and as a marketing technique, have invented scientific-sounding names for the strains. Danone (Dannon in the United States) markets the subspecies strain DN 173 010 as Bifidus Digestivum (UK), Bifidus Regularis (US and Mexico), Bifidobacterium Lactis or B.L. Regularis (Canada), DanRegularis (Brazil), Bifidus Actiregularis (Argentina, Austria, Belgium, Bulgaria, Chile, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Kazakhstan, Netherlands, Portugal, Romania, Russia, South Africa, Spain and the UK), and Bifidus Essensis in the Middle East (and formerly in Hungary, Bulgaria, Romania and The Netherlands) through Activia from Safi Danone KSA. One notable example involved Danone’s attempt to enforce a trademark on an invented probiotic strain name. Danone held a trademark for “Bifidus Essensis”, which it used in marketing its Activia products, and sued Glanbia after the launch of Yoplait “Essence” products in the Irish market, claiming trademark infringement. In 2007, the Irish Commercial Court ruled against Danone, finding that the “Essensis” trademark had not been genuinely used as a product brand in the relevant market and ordering its revocation in that context. Chr. Hansen A/S from Denmark has a similar claim on a strain of Bifidobacterium animalis subsp. lactis, marketed under the trademark BB-12. Lidl lists "Bifidobacterium BB-12" in its "Proviact" yogurt. Bifidobacterium lactis Bl-04 and Bi-07 are strains from DuPont's Danisco FloraFIT range.
=== Supercritical water hydrolysis === Supercritical hydrolysis is a method of converting all biomass polysaccharides as well the associated lignin into low molecular compounds by contacting with water alone under supercritical conditions. The supercritical water, acts as a solvent, a supplier of bond-breaking thermal energy, a heat transfer agent and as a source of hydrogen atoms. All polysaccharides are converted into simple sugars in near-quantitative yield in a second or less. The aliphatic inter-ring linkages of lignin are also readily cleaved into free radicals that are stabilized by hydrogen originating from the water. The aromatic rings of the lignin are unaffected under short reaction times so that the lignin-derived products are low molecular weight mixed phenols. To take advantage of the very short reaction times needed for cleavage a continuous reaction system must be devised. The amount of water heated to a supercritical state is thereby minimized.
Light output is approximately proportional to V 3.4 Power consumption is approximately proportional to V 1.6 Lifetime is approximately proportional to V −16 Color temperature is approximately proportional to V 0.42 A 5% reduction in voltage will double the life of the bulb, but reduce its light output by about 16%. Long-life bulbs take advantage of this trade-off in applications such as traffic signal lamps. Since electric energy they use costs more than the cost of the bulb, general service lamps emphasize efficiency over long operating life. The objective is to minimize the cost of light, not the cost of lamps. Early bulbs had a life of up to 2500 hours, but in 1924 the Phoebus cartel agreed to limit life to 1000 hours. When this was exposed in 1953, General Electric and other leading American manufacturers were banned from limiting the life. The relationships above are valid for only a few percent change of voltage around standard rated conditions, but they indicate that a lamp operated at low voltage could last much longer than at rated voltage, albeit with greatly reduced light output. The "Centennial Light" is a light bulb that is accepted by the Guinness Book of World Records as having been burning almost continuously at a fire station in Livermore, California, since 1901. However, the bulb emits the equivalent light of a four watt bulb. A similar story can be told of a 40-watt bulb in Texas that has been illuminated since 21 September 1908.
Sources: en.wikipedia.org
==== Point contact on a (3D) half-space ==== Analogously to the Flamant solution for the 2D half-plane, fundamental solutions are known for the linearly elastic 3D half-space as well. These were found by Boussinesq for a concentrated normal load and by Cerruti for a tangential load. See the section on this in Linear elasticity.
== Doping in sports == Thymosin beta-4 (and/or its derivative TB-500) was allegedly used by some players in various Australian football codes and is under investigation by the Australian Sports Anti-Doping Authority for anti-doping violations.
Chemical/topical – This is a topical agent often used in surgery settings to stop bleeding. Microfibrillar collagen is the most popular choice among surgeons [recent source?] because it attracts the patient's natural platelets and starts the blood clotting process when it comes in contact with the platelets. This topical agent requires the normal hemostatic pathway to be properly functional. Direct pressure or pressure dressing – This type of hemostasis approach is most commonly used in situations where proper medical attention is not available. Putting pressure and/or dressing to a bleeding wound slows the process of blood loss, allowing for more time to get to an emergency medical setting. Soldiers use this skill during combat when someone has been injured because this process allows for blood loss to be decreased, giving the system time to start coagulation. Sutures and ties – Sutures are often used to close an open wound, allowing for the injured area to stay free of pathogens and other unwanted debris to enter the site; however, it is also essential to the process of hemostasis. Sutures and ties allow for skin to be joined back together allowing for platelets to start the process of hemostasis at a quicker pace. Using sutures results in a quicker recovery period because the surface area of the wound has been decreased. Physical agents (gelatin sponge) – Gelatin sponges have been indicated as great hemostatic devices. Once applied to a bleeding area, a gelatin sponge quickly stops or reduces the amount of bleeding present.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.